Metformin and sulfonylureas are the most heavily prescribed type 2 diabetes drugs and dominate the early lines of therapy, before disease progression requires insulin replacement. The emergence of more-effective, safer, and/or better-tolerated therapies, such as the sodium glucose contransporter-2 (SLGT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists, have provided physicians with a broad array of therapeutic options. Moreover, with better understanding of type 2 diabetes and its complications, individualization of treatment is becoming more common. Numerous branded agents from both established and recently emergent classes are now jostling for position in the treatment paradigm.
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed type 2 diabetes patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed type 2 diabetes patients?
- How have Steglatro, Ozempic, Rybelsus, and Tresiba been integrated into the treatment algorithm, and what are their sources of business?
- What percentage of type 2 diabetes patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of type 2 diabetes patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
- Type 2 Diabetes - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)
Author(s): Shambhavi Shukla
Shreya Saxena is a senior business insights analyst in the Cardiovascular, Metabolic and Renal disorders team at Decision Resources Group.
She obtained an M.B.A. degree with specializations in Marketing and HR, and a Bachelor's degree in Pharmacy from the GGSIPU University, Delhi, India. Prior to joining DRG, she has worked as a Business Analyst at the research firm Evalueserve. Her role involved in-depth commercial, and scientific secondary research, and competitive intelligence across multiple indications (such as atrial fibrillation, ACS, VTE, heart failure and women’s health), including pipeline analysis, clinical trials assessment, disease landscaping, product and company profiling, and financial assessment and benchmarking.